Currently, there are 38.90M common shares owned by the public and among those 33.57M shares have been available to trade.
The company’s stock has a 5-day price change of 76.88% and 49.34% over the past three months. LBPH shares are trading 878.28% year to date (YTD), with the 12-month market performance up to 1049.90% higher. It has a 12-month low price of $3.60 and touched a high of $43.15 over the same period. LBPH has an average intraday trading volume of 664.20K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 69.53%, 69.24%, and 128.34% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Longboard Pharmaceuticals Inc (NASDAQ: LBPH) shares accounts for 99.76% of the company’s 38.90M shares outstanding.
It has a market capitalization of $2.29B and a beta (3y monthly) value of 1.24. The earnings-per-share (ttm) stands at -$2.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.09% over the week and 9.82% over the month.
Earnings per share for the fiscal year are expected to increase by 7.95%, and -25.52% over the next financial year.
Looking at the support for the LBPH, a number of firms have released research notes about the stock. Truist stated their Buy rating for the stock in a research note on September 10, 2024, with the firm’s price target at $60. Cantor Fitzgerald coverage for the Longboard Pharmaceuticals Inc (LBPH) stock in a research note released on July 01, 2024 offered a Overweight rating with a price target of $90. Robert W. Baird was of a view on May 01, 2024 that the stock is Outperform, while Citigroup gave the stock Buy rating on February 16, 2024, issuing a price target of $40. Cantor Fitzgerald on their part issued Overweight rating on October 24, 2023.
